SCHEMBL3781567

SCHEMBL3781567

CCCCCCCC(O)C(C(=O)O)C(=O)CC(O)CCCCCCCC1O[C@H](C)[C@@H](O)[C@H](O)[C@@H]1O

nearest known ligand 0.42

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 7/20 0.42
TLR4 O00206 1/20 0.36
DAGLA Q9Y4D2 1/20 0.36
TBXA2R P21731 1/20 0.36
PTGFR P43088 1/20 0.36
PTGER2 P43116 1/20 0.36
SELP P16109 6/20 0.36
SELL P14151 5/20 0.36
FFAR1 O14842 2/20 0.35
FFAR4 Q5NUL3 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL374097 1.00 GPR84 (0.42) GPR84TLR4DAGLATBXA2RPTGFR
SCHEMBL17294503 1.00 GPR84 (0.42) GPR84TLR4DAGLATBXA2RPTGFR
SCHEMBL14957946 1.00 GPR84 (0.42) GPR84TLR4DAGLATBXA2RPTGFR
SCHEMBL14332067 1.00 GPR84 (0.42) GPR84TLR4DAGLATBXA2RPTGFR
SCHEMBL8013415 1.00 GPR84 (0.42) GPR84TLR4DAGLATBXA2RPTGFR
SCHEMBL10534787 1.00 GPR84 (0.42) GPR84TLR4DAGLATBXA2RPTGFR
SCHEMBL17001438 0.89 TLR4 (0.34) GPR84TLR4TBXA2RPTGFRPTGER2
SCHEMBL5055853 0.88 SELL (0.41) GPR84TLR4SELPSELL
SCHEMBL8026363 0.88 SELL (0.41) GPR84TLR4SELPSELL
SCHEMBL9129668 0.83 GPR84 (0.33) GPR84DAGLATBXA2RPTGFRPTGER2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190118017-A1 RHAMNOLIPID COATED NANOSCALE ZEROVALENT IRON EMULSIONS AND METHOD OF USE THEREOF THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2019-04-25 US claimed
WO-2017177336-A1 RHAMNOLIPID COATED NANOSCALE ZEROVALENT IRON EMULSIONS AND METHOD OF USE THEREOF THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2017-10-19 WO claimed
US-20240182513-A1 SEPARATION OF METAL IONS FROM A SAMPLE USING GLYCOLIPIDS ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA 2024-06-06 US disclosed
WO-2023278801-A1 SEPARATION OF METAL IONS FROM A SAMPLE USING GLYCOLIPIDS ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2023-01-05 WO disclosed
US-10801053-B2 Process for producing a rhamnolipid produced by Pseudomonas or Enterobacter using andiroba or murumuru seed waste NATURA COSMETICOS S/A (BR) 2020-10-13 US disclosed
US-20200115729-A1 PROCESS FOR PRODUCING A RHAMNOLIPID PRODUCED BY PSEUDOMONAS OR ENTEROBACTER USING ANDIROBA OR MURUMURU SEED WASTE INSTITUTO DE PESQUISAS TECNOLOGICAS DO ESTADO DE SAO PAULO S.A. - IPT (BR) 2020-04-16 US disclosed
EP-3569714-A1 PROCESS FOR PRODUCING A RHAMNOLIPID PRODUCED BY PSEUDOMONAS OR ENTEROBACTER USING ANDIROBA OR MURUMURU SEED WASTE Natura Cosméticos S.A. (BR) 2019-11-20 EP disclosed
US-10344304-B2 Materials derived from fermentation-produced rhamnolipids and methods of production THE UNIVERSITY OF AKRON (US) 2019-07-09 US disclosed
US-20190118017-A1 RHAMNOLIPID COATED NANOSCALE ZEROVALENT IRON EMULSIONS AND METHOD OF USE THEREOF THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2019-04-25 US disclosed
US-9992998-B2 Rhamnolipid based biopesticides THE UNIVERSITY OF AKRON (US) 2018-06-12 US disclosed
WO-2017177336-A1 RHAMNOLIPID COATED NANOSCALE ZEROVALENT IRON EMULSIONS AND METHOD OF USE THEREOF THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2017-10-19 WO disclosed
US-20170175151-A1 NOVEL MATERIALS DERIVED FROM FERMENTATION-PRODUCED RHAMNOLIPIDS AND METHODS OF PRODUCTION THE UNIVERSITY OF AKRON 2017-06-22 US disclosed
US-9468700-B2 Wound dressings with enhanced gas permeation and other beneficial properties THE UNIVERSITY OF AKRON (US) 2016-10-18 US disclosed
US-20140364381-A1 WOUND DRESSINGS WITH ENHANCED GAS PERMEATION AND OTHER BENEFICIAL PROPERTIES THE UNIVERSITY OF AKRON 2014-12-11 US disclosed
WO-2010080406-A1 METHOD FOR TREATING RHINITIS AND SINUSITIS BY RHAMNOLIPIDS ADREM BIOTECH, INC. (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240182513-A1 SEPARATION OF METAL IONS FROM A SAMPLE USING GLYCOLIPIDS SGMS2, SGMS1, UGCG GPR84 3741/4885TLR4 4473/4885DAGLA 133/4885
US-10344304-B2 Materials derived from fermentation-produced rhamnolipids and methods of production HACL2, COASY, FASN GPR84 1041/4885TLR4 4041/4885DAGLA 23/4885
US-20170175151-A1 NOVEL MATERIALS DERIVED FROM FERMENTATION-PRODUCED RHAMNOLIPIDS AND METHODS OF PRODUCTION HACL2, COASY, FASN GPR84 968/4885TLR4 3964/4885DAGLA 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.